- Home
- RFI vs AVIR Comparison
RFI vs AVIR Comparison
Compare RFI & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFI
- AVIR
- Stock Information
- Founded
- RFI 1992
- AVIR 2012
- Country
- RFI United States
- AVIR United States
- Employees
- RFI N/A
- AVIR N/A
- Industry
- RFI Investment Managers
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- RFI Finance
- AVIR Health Care
- Exchange
- RFI Nasdaq
- AVIR Nasdaq
- Market Cap
- RFI 344.7M
- AVIR 290.4M
- IPO Year
- RFI N/A
- AVIR 2020
- Fundamental
- Price
- RFI $12.73
- AVIR $3.56
- Analyst Decision
- RFI
- AVIR Hold
- Analyst Count
- RFI 0
- AVIR 1
- Target Price
- RFI N/A
- AVIR $6.88
- AVG Volume (30 Days)
- RFI 69.8K
- AVIR 152.3K
- Earning Date
- RFI 01-01-0001
- AVIR 11-06-2024
- Dividend Yield
- RFI 8.25%
- AVIR N/A
- EPS Growth
- RFI N/A
- AVIR N/A
- EPS
- RFI N/A
- AVIR N/A
- Revenue
- RFI N/A
- AVIR N/A
- Revenue This Year
- RFI N/A
- AVIR N/A
- Revenue Next Year
- RFI N/A
- AVIR N/A
- P/E Ratio
- RFI N/A
- AVIR N/A
- Revenue Growth
- RFI N/A
- AVIR N/A
- 52 Week Low
- RFI $9.62
- AVIR $2.77
- 52 Week High
- RFI $12.52
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- RFI 44.70
- AVIR 49.38
- Support Level
- RFI $12.88
- AVIR $3.31
- Resistance Level
- RFI $13.14
- AVIR $3.86
- Average True Range (ATR)
- RFI 0.17
- AVIR 0.12
- MACD
- RFI -0.02
- AVIR 0.03
- Stochastic Oscillator
- RFI 21.74
- AVIR 46.90
About RFI Cohen & Steers Total Return Realty Fund Inc.
Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).